New MOTS-c Study (2026): Better Muscle Mitochondrial Quality via PGC-1α and AMPK, Not More Mitochondria

MOTS-c is a peptide your own mitochondria write into existence — a short open reading frame tucked inside the 12S ribosomal RNA region of mitochondrial DNA, translated into a 16-amino-acid peptide that turns up in muscle, blood, and nucleus.¹² Since its 2015 discovery it has been tied to insulin sensitivity, resistance to diet-induced obesity, and exercise adaptation, mostly through the AMPK energy-sensing pathway.² A 2026 paper from the University of Copenhagen asks a narrower, more mechanistic question that the earlier systemic-metabolism work stepped past: what does MOTS-c do to the bioenergetic machinery inside the mitochondrion itself?¹ Everything below describes laboratory and literature findings in mice and cells — not use in people.

What is MOTS-c, and what did the 2026 study set out to test?

MOTS-c — the “mitochondrial open reading frame of the 12S rRNA type-c” — belongs to a small class of mitochondrial-derived peptides that includes humanin and the SHLPs.⁶ Lee and colleagues identified it in 2015 as an activator of AMPK that promotes metabolic homeostasis and blunts diet-induced obesity and insulin resistance in mice.² Reynolds and colleagues later showed it is exercise-induced, translocates to the nucleus, and regulates adaptive gene expression, with MOTS-c treatment improving physical capacity and attenuating age-related decline in mice.³ You can read the fuller background in our explainers on what MOTS-c is and on how mitochondria secrete hormone-like peptides.

The gap the 2026 study targets is specific. Most prior work measured whole-body or whole-cell outcomes — glucose handling, body weight, insulin sensitivity — and treated the mitochondrion as a black box.⁸ Gudiksen, Pilegaard and colleagues at the August Krogh Section instead went inside skeletal muscle to measure intrinsic mitochondrial bioenergetics: respiration, efficiency, and reactive oxygen species emission, and whether any effect depended on the two canonical energy-sensing regulators, PGC-1α and AMPK.¹

The PGC-1α/AMPK axis, and why it is the right place to look

The link between AMPK and PGC-1α is one of the better-established pieces of muscle biology. Jäger and colleagues showed in 2007 that AMPK directly phosphorylates PGC-1α, and that this phosphorylation is required for AMPK-dependent induction of PGC-1α and its downstream mitochondrial and metabolic genes.⁴ AMPK reads the cell’s energy charge; PGC-1α is the transcriptional coactivator that reshapes mitochondrial content and quality in response. That axis is the throughline of the exercise-mimetic literature and of AMPK-activator research more broadly, which we cover in our AICAR and AMPK guide.

MOTS-c already had a foot in this door. Yang and colleagues reported in 2021 that, in mice, MOTS-c combined with exercise regulated PGC-1α expression, attenuated insulin resistance, and enhanced glucose metabolism through AMPK signaling.⁵ What the 2026 study adds is causal dependence at the level of muscle mitochondrial function — not just correlation with PGC-1α expression, but a requirement for both PGC-1α and AMPK for the bioenergetic effect to appear.¹

The headline result: better mitochondria, not more of them

Using two distinct transgenic mouse strains — one to interrogate PGC-1α dependence, one for AMPK — the authors report that exogenous MOTS-c augmented skeletal-muscle mitochondrial bioenergetic performance, and that this augmentation was dependent on both regulators.¹ The finding that gives the paper its edge is a negative one: there was no change in mitochondrial respiratory protein content. The muscle did not build more mitochondrial machinery. Instead, the existing machinery ran better.

2 transgenic mouse strains were used to show the effect required both PGC-1α and AMPK — remove either, and the bioenergetic benefit did not hold.

Alongside improved efficiency, MOTS-c lowered mitochondrial reactive oxygen species emission and reduced ROS-related protein damage — a marker of oxidative stress inside the organelle.¹ RNA sequencing rounded out the picture but modestly: the authors describe subtle effects across redox handling, mitochondrial integrity, and OXPHOS efficiency, rather than a dramatic transcriptional rewrite. The mechanistic story, then, is quality over quantity — a cleaner-running mitochondrion, not a more populous one.

The muscle did not make more mitochondria. It made the ones it had run more efficiently and emit less oxidative damage.

All rows summarize findings in transgenic mice and one human arm from a single study. In-vitro / literature only; no human muscle functional effect was demonstrated. Not a dosing or use protocol.

The human arm — and why it matters that it was null

The same paper included a human experiment, and it is the part most worth reading carefully. Despite raising interstitial MOTS-c, the authors found no change in the arterio-venous difference during one-legged knee-extensor exercise.¹ In plain terms: they could not detect the muscle taking up or releasing MOTS-c in a way that tracked the manipulation, which led them to suggest that skeletal muscle may not be the source of circulating MOTS-c during exercise. That runs against a common assumption in the field and is exactly the kind of null result that responsible authors report rather than bury. It also means the study does not demonstrate a functional MOTS-c effect in human muscle — the mechanistic weight sits entirely on the mouse data.

An honest read of the evidence

This is one mechanistic study from a single laboratory, and it has not been independently replicated. The core positive findings — PGC-1α/AMPK dependence, improved intrinsic quality without biogenesis, lower ROS — all come from mice, and specifically from two transgenic, genetically engineered strains rather than wild-type animals or humans. Mechanistic “dependence” was inferred by knocking out or altering a regulator and watching the effect disappear; that is a strong design, but it is a statement about engineered biology, not about a normal human muscle. The human arm, meanwhile, was null for its own hypothesis and actively argues that muscle is not the exercise source of circulating MOTS-c — so the paper contains its own caution against over-reading the mouse story into people.

The RNA-seq layer deserves the same restraint the authors used: they call the effects “subtle” and “potential,” which describes molecular signatures, not large or settled functional shifts. And exogenous MOTS-c given to a mouse under controlled conditions tells you little about how the peptide behaves under different species, doses, or delivery routes. The wider MOTS-c and longevity literature reinforces this gap. Human data are still mostly observational — D’Souza and colleagues, for instance, reported that muscle MOTS-c expression varies with aging and myofiber composition, which is association, not intervention.⁷ Reviews of MOTS-c in human aging make the same scoping point: the promise is real, the human interventional evidence is not yet there.⁹ The honest headline is that this is a clean, well-controlled animal mechanism paper with a null human arm — informative for how the peptide might work, silent on whether it does anything useful in a person.

All materials supplied by Condor Research are Research Use Only (RUO). The findings above are drawn from in-vitro, animal, and literature sources and are provided for scientific reference only. Nothing here is a dosing protocol, clinical guidance, or a safety assessment for any organism, and none of it describes or endorses use in humans or animals.

Condor Research · Scientific desk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com